Strata Critical Medical, Inc. SRTA R2K
Company Overview
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals. The company was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
Why Investors Should Care
Net profit has compounded at 217.7% per year over the last five years.
Revenue has grown at a 36.0% CAGR over the past five years.
Maintains a net profit margin of 20.6%.
Recent Developments
- Dec 2025 Revenue of $197.14M (+34.3% YoY); net profit $41.35M.
- Trailing 12 Months Year-on-year growth — revenue +87.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 36.0%, profit CAGR 217.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 35.97% |
| 1 Year: | 87.40% |
Compounded Profit Growth
| 5 Years: | 217.72% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +30.60% |
| 6 Months: | -6.39% |
| 3 Months: | +25.17% |
| 1 Month: | -0.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)50.62 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 20.6%.
- Compounding revenue at 36.0% over 5 years.
- Profit CAGR of 217.7% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SRTA Strata Critical Medical, Inc. R2K | 5.42 | -28.53 | $468.97M | 0.00% | -7.31% | -6.35% | 35.97% | 217.72% |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 3.44M | - | 9.27M | 12.95M | 20.32M | 24.62M | 26.63M | 35.63M | 45.72M | - | 45.27M | 60.99M | 71.44M | 51.51M | 67.94M | 36.06M | 35.95M | 70.80M | 49.30M | 67.38M |
| Gross Profit | - | - | - | - | - | - | - | - | 2.92M | 5.11M | 9.27M | - | 7.16M | 10.37M | 15.58M | - | - | - | 7.05M | - | - | 14.12M |
| Operating Income | -43.05K | -145.13K | -1.48M | -160.69K | -4.22M | -7.77M | -9.73M | -10.54M | -13.69M | -9.73M | -10.43M | - | -12.83M | -12.21M | -7.45M | -9.87M | -12.15M | -7.09M | -5.68M | -4.95M | -5.62M | -2.97M |
| Net Income | 99.14K | 5.70M | -1.32M | -100.16K | -4.22M | -24.29M | -9.18M | 772.00K | -11.01M | 8.41M | -9.24M | -27.26M | -10.19M | -12.23M | 289.00K | -4.23M | -11.33M | -1.95M | -3.49M | -3.74M | 57.42M | 2.15M |
| Diluted EPS | - | - | - | - | -0.16 | -0.47 | -0.13 | 0.01 | -0.16 | 0.10 | -0.13 | - | -0.14 | -0.17 | 0.00 | -0.06 | -0.15 | -0.03 | -0.04 | -0.05 | 0.70 | 0.03 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2019 | Sep 2020 | Dec 2020 | Sep 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 31.20M | 23.43M | - | 50.53M | 146.12M | 225.18M | 146.82M | 197.14M |
| Gross Profit | - | - | - | - | - | - | 29.59M | 41.13M |
| Operating Income | -11.54M | -10.36M | -678.49K | -24.09M | -53.53M | -68.12M | -22.52M | -22.35M |
| Net Income | -10.84M | -10.16M | 127.72K | -40.05M | -27.26M | -56.08M | -27.31M | 41.35M |
| Diluted EPS | -0.43 | -0.40 | - | -0.93 | -0.38 | -0.76 | -0.35 | 0.50 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2018 | May 2019 | Sep 2019 | Dec 2019 | Sep 2020 | Dec 2020 | Sep 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 277.69M | 17.71M | 277.84M | 343.39M | 335.88M | 325.02M | 294.94M | 256.68M | 325.47M |
| Total Equity | 31.14M | 0 | 20.73M | 5.00M | 11.08M | 5.00M | 291.23M | 291.37M | 274.49M | 234.30M | 221.94M | 279.07M |
| Cash & Equivalents | - | - | 22.18M | 1.31M | 12.16M | 846.07K | 6.95M | 2.60M | 41.34M | 27.87M | 18.38M | 30.97M |
| Long Term Debt | - | - | - | - | - | - | - | - | 0 | - | - | - |
| Total Liabilities | - | - | - | 10.00M | 6.63M | 10.02M | 52.16M | 44.51M | 50.54M | 60.64M | 34.74M | 46.40M |
| Current Liabilities | - | - | - | 371.31K | 6.34M | 390.79K | 9.53M | 12.78M | 26.61M | 35.49M | 22.73M | 19.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2019 | Sep 2020 | Dec 2020 | Sep 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.30M | -10.82M | -794.47K | -15.62M | -37.13M | -32.35M | -2.52M | -48.91M |
| Investing Cash Flow | -1.05M | -377.00K | 334.93K | -321.34M | 79.34M | 17.09M | -1.02M | 69.75M |
| Financing Cash Flow | 116.00K | 1.18M | - | 332.26M | -1.08M | -76.00K | -5.76M | -8.91M |
| Capital Expenditure | -604.00K | -377.00K | - | -297.00K | -730.00K | -2.11M | -30.86M | -9.60M |
| Free Cash Flow | -10.91M | -11.20M | - | -15.91M | -37.86M | -34.46M | -33.38M | -58.51M |
| Share Buybacks | - | - | - | - | - | 0 | 244.00K | 0 |
Ratios (Annual)
Figures in %.
| Metric | Sep 2019 | Sep 2020 | Dec 2020 | Sep 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | 20.2% | 20.9% |
| Operating Margin % | -37.0% | -44.2% | - | -47.7% | -36.6% | -30.3% | -15.3% | -11.3% |
| Net Margin % | -34.7% | -43.4% | - | -79.3% | -18.7% | -24.9% | -18.6% | 21.0% |
| ROE % | -52.3% | -91.7% | 2.6% | -13.8% | -9.9% | -23.9% | -12.3% | 14.8% |
| ROCE % | - | -91.1% | -0.2% | -7.2% | -17.9% | -26.3% | -9.6% | -7.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | ARK Investment Management, LLC | 8.62% | 7.46M | $39.81M |
| 2 | Third Point, LLC | 5.78% | 5.00M | $26.70M |
| 3 | Blackrock Inc. | 5.28% | 4.57M | $24.40M |
| 4 | Northern Right Capital Management, L.P. | 4.73% | 4.09M | $21.84M |
| 5 | Vanguard Capital Management LLC | 3.32% | 2.87M | $15.34M |
| 6 | AWM Investment Company, Inc. | 3.26% | 2.82M | $15.07M |
| 7 | Royce & Associates LP | 3.25% | 2.82M | $15.04M |
| 8 | Pillsbury Lake Capital LLC | 3.01% | 2.60M | $13.90M |
| 9 | First Eagle Investment Management, LLC | 2.62% | 2.27M | $12.10M |
| 10 | Geode Capital Management, LLC | 1.96% | 1.70M | $9.08M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SRTA
Strata Critical Medical, Inc. (SRTA) Surges 8.5%: Is This an Indication of Further Gains? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQSWR2NjQ5aVk5TjZ2cGdjVWdGVnZORjUzQkdPSVJ0Y2dVdGlhb1lHUHBsZkk1ZTZYUVNfWlAxME03T2pxc2lSaGdIemkwOGQ5ZHdDLXpFbm1BaGU5MENQZEJLdURmcUJ5YkxYZWtGamlOWGZqTGwzOXFCcVE5RWJON21LeUlnMmtxY2RrMU…
Enterprise value to EBIT forward of Strata Critical Medical, Inc. – NASDAQ:SRTA - TradingView
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPOXM3VkZvc0hqY3VLOC1iRFc1UTVqR0Y0WDlxT0JVd0tENDEyWXMyekZWc0t3WFJNQ2FDUTQ2SlhaQjlCRmhvYXdRZlRNOWVGTDItM0xXbFVid1J1ckMtQm9rLXk5QU04SzRiM3FidnRQRktrZnJOUF9Qc0tzbmJCZWhSOGhQV1B6cVM1Ul…
MSN Money - MSN
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOS2JwVkpFenp2S3BfQ2d4aGhDRGwyTl8zdEFtd2M1UlpwNl9VMkVrN3lLOTFLcW9jTWtZb0xrczlaVnoySzdYdG9IckFMV2dQSW9oLVkteWp0cjZhaTdGSXNqU25KeS1CVVF3ZUdVRDJsdVZUOWh1cjdwaVNIRGdPS0RCTTJXQ29wSmVvQm…
Strata adds transplant surgeons in Florida and California - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQNS0wWUxJLUJTMWNvb1BTRzFzTHVNSHBTZXpsVTNZUTdEVGhiRm5EVnFDMTlnemRueUJGeXFjOFBXeUszTDV3Y1lWMGFBSWYzTDdWSWI5UVQ4cWd6UVM3LThWVmRwVWwyZDNjdk4xUW1UOW1fX0lrdHBmbDV1TDVieE4tRlhXdGUtTnZwb0…
Strata Critical Medical Inc. (SRTA) Holds Near Key Support Amid Modest Pullback - Golden Cross - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPeFhzUDY2cEVTSkdSOVphNlNlOXpHaEQ2WWZoU2pjSzhLN0RSUk9OM0xyVGg4a3lkUjFObExUZVlCcmtmTXFCNjhtYmhfMWFMM05MbFNTcnFqYkQwbTEzWm4yY0FoeXUya3J2OWZ1OW5OeVY1dnZBOVZDRXYyamZQSGpMaXNETFEyYmc3a2…
Cathie Wood’s ARK sells Strata Critical Medical stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNaEg5UlY0NUtfSTFtUTdSR1E5d0QtblRYRmxyTzl6RlZ6Wmp0Wk9mUGZyV2h0eUlRNkJ5a0psdENiZ2hLeXJCNnZXcUhVMVlHUXRPZU5RX0pJSG5URklUUW5PTE9vZVlfeFZocTE0YVhRTFJtWWFUYl9oNzlOb1RvX24yZHc2OTlXQ0VBM1…
SRTA — Frequently Asked Questions
What is the current share price of Strata Critical Medical, Inc. (SRTA)?
As of 2026-07-15 16:51 PDT, Strata Critical Medical, Inc. (SRTA) trades at $5.42 on NasdaqCM. Its 52-week range is $3.77 to $6.47.
What is the market capitalisation of SRTA?
Strata Critical Medical, Inc. (SRTA) has a market capitalisation of $468.97M on NasdaqCM.
What is the P/E ratio of SRTA?
SRTA trades at a trailing price-to-earnings (P/E) ratio of -28.53. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.62.
What is the return on equity (ROE) of SRTA?
SRTA has a return on equity (ROE) of -6.35%. Its return on capital employed (ROCE) is -7.31%.
Is SRTA a good stock to buy?
This page provides a data-driven analysis of Strata Critical Medical, Inc. (SRTA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.